SPARC and familial pancreatic carcinoma: In resected pancreatic cancer, SPARC stromal and cytoplasmic overexpression was associated with statistically significant worse disease-free survival (DFS) and OS in those treated with adjuvant gemcitabine, and not 5-fluorouracil, suggesting that SPARC may have a role as a predictive marker [6].